Session Information

  • WCLC 2020

    2020 World Conference on Lung Cancer

    Conference Program for the 2020 World Conference on Lung Cancer in Singapore


    Presentation Date(s):  
    • January 28 - 31, 2021
    • Total Presentations: 1597

    All times listed are in Singapore time (GMT+8)

    PL - Plenary
    PS - Presidential Symposium
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    IS - Industry Symposium
    JICC - Joint IASLC-CAALC-CSCO Session

Filter Results:

Show Only CME Accredited Sessions

  • +

    FP13 - Immunotherapy (Phase II/III Trials)

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Type: Posters (Featured)
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      FP13.01 - 5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel in Previously Treated, PD-L1–Positive Advanced NSCLC

      00:00 - 00:00  |  Presenter: Roy S. Herbst

      • Abstract

      Loading...

    • +

      FP13.02 - Pembrolizumab + Pemetrexed-Platinum vs Pemetrexed-Platinum for Metastatic NSCLC: 4-Year Follow-up From KEYNOTE-189

      00:00 - 00:00  |  Presenter: Jhanelle Elaine Gray

      • Abstract

      Loading...

  • +

    P01 - Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
    • +

      P01.21 - ANSELMA: Antiangiogenic Second Line Lung Cancer Meta-Analysis on Individual Patient Data in Non-Small Cell Lung Cancer, Again Relevant in ICI Era

      00:00 - 00:00  |  Presenter: Jordi Remon

      • Abstract

      Loading...

  • +

    P15 - Immuno-biology and Novel Immunotherapeutics (Phase I and Translational) - Novel Immunotherapeutics (Phase I)

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
    • +

      P15.08 - Phase I Trial of in situ Vaccination With Autologous CCL21-Modified Dendritic Cells (CCL21-DC) Combined With Pembrolizumab for Advanced NSCLC

      00:00 - 00:00  |  Presenter: Aaron Lisberg

      • Abstract

      Loading...

  • +

    P85 - Targeted Therapy - Clinically Focused - MET

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Targeted Therapy - Clinically Focused
    • +

      P85.04 - Capmatinib in Patients with METex14-Mutated Non-Small Cell Lung Cancer: GEOMETRY Mono-1 Asian Subgroup Analysis 

      00:00 - 00:00  |  Presenter: Ji-Youn Han

      • Abstract

      Loading...

  • +

    OA01 - Established Drugs in Special Populations and New Drugs in Established Populations

    • 09:15 - 10:15
    • 1/29/2021
    • Location: Scientific Program Auditorium
    • IASLC CME Accredited
    • Type: Oral
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      OA01.05 - Discussant

      09:35 - 09:40  |  Presenter: Edward B. Garon

      • Abstract

      No abstract available for this presentation

  • +

    OA03 - Promising Antibody-Drug Conjugate and Cytotoxic Therapy in NSCLC

    • 10:30 - 11:30
    • 1/29/2021
    • Location: Scientific Program Auditorium
    • IASLC CME Accredited
    • Type: Oral
    • Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
    • +

      OA03.03 - Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study

      10:30 - 10:40  |  Presenter: Alex I. Spira

      • Abstract

      Loading...

  • +

    PS01 - Presidential Symposium (Japanese, Mandarin, Spanish Translation Available)

    • 07:00 - 09:00
    • 1/30/2021
    • Location: Scientific Program Auditorium
    • IASLC CME Accredited
    • Type: Plenary
    • Track: N.A.
    • +

      PS01.05 - Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis

      07:30 - 07:40  |  Presenter: Jay M. Lee

      • Abstract

      Loading...

  • +

    PS02 - Presidential Symposium (Re-Broadcast) (Japanese, Mandarin, Spanish Translation Available)

    • 18:00 - 20:00
    • 1/30/2021
    • Location: Scientific Program Auditorium
    • IASLC CME Accredited
    • Type: Plenary
    • Track: N.A.
    • +

      PS02.05 - Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis

      18:30 - 18:40  |  Presenter: Jay M. Lee

      • Abstract

      Loading...